Strategy, Structure, and Digital Readiness for the New CMC Quality Module 

After two decades, the “Gold Standard” for drug quality submissions has evolved. In early 2026, the FDA and ICH moved the M4Q(R2) Draft Guidance into its critical public consultation and pilot phase. This isn’t just a minor edit—it is a total architectural redesign of how we present drug quality data.

The 2026 update shifts the Quality Overall Summary (Module 2.3) from a simple summary to a “Strategic Core” and transforms Module 3 into a granular, standardized data repository. This webinar breaks down the new DMCS (Description, Manufacture, Control, Storage) model and the strategic move toward structured, digital-first submissions.

Why You Should Attend

The window for “business as usual” is closing. Professionals who master the M4Q(R2) framework now will be able to:

• Eliminate Redundancy: Learn the new “Core Quality Information” (CQI) approach to stop repeating data between Modules 2 and 3.
• Accelerate Approvals: Understand the “Overall Control Strategy” (OCS) backbone that reviewers now use to assess product risk.
• Future-Proof Your Dossiers: Align your CMC strategy with ICH M16 (Structured Product Quality Submissions) to ensure your data is ready for the digital-first era.
• Reduce Post-Approval Burden: Use the new “Established Conditions” (ECs) sections to streamline future manufacturing changes.

Topics to be Covered

1. The Architectural Shift: Module 2.3 vs. Module 3.2

• Moving from a narrative-heavy Quality Overall Summary (QOS) to a Core Quality Information (CQI) model.
• How Module 3.2 now serves as a technical data repository using the DMCS standardized template.

2. The “Backbone”: Overall Control Strategy (OCS)

• Integrating the Quality Target Product Profile (QTPP) and Critical Quality Attributes (CQAs) into a unified narrative.
• How to present “Justifications” in the new Development Summary and Justification (DSJ) section.

3. The DMCS Model for Materials

Standardizing the presentation of Drug Substance and Drug Product information:

• Description (Identification & Characteristics)
• Manufacture (Process & IPCs)
• Control (Specifications & Analytical Procedures)
• Storage (Stability & Container Closure)

4. Special Focus: Complex Modalities & Lifecycle

• Adapting the M4Q(R2) for Cell & Gene Therapies, mRNA vaccines, and Combination Products.
• The relationship between M4Q(R2) and ICH Q12 (Lifecycle Management).

5. Case Study: The “Sakura Bloom R2” Mock Example

• A practical walkthrough of a small-molecule submission using the 2026 format.
• Common pitfalls in cross-referencing between granular data sections.

Who Will Benefit?

This session is essential for those responsible for the integrity and success of global regulatory filings:

• CMC Regulatory Affairs Managers: To lead the transition of legacy dossiers to the new R2 structure.
• Quality Assurance (QA) Professionals: To ensure manufacturing site data aligns with the standardized DMCS format.
• Pharmaceutical Development Scientists: To better document the “scientific rationale” required for the DSJ section.
• Regulatory Operations & Publishers: To master the new cross-referencing and “granular” folder structures required for eCTD 4.0.
• Biotech Executives: To understand how these changes impact the “speed-to-market” for innovative therapies.

Learning Objectives

By the conclusion of this webinar, participants will:

1. Differentiate between “Core Quality Information” and “Supportive Data” to prevent dossier bloat.
2. Apply the DMCS template to both Drug Substance and Drug Product modules.

Construct a high-level “Overall Control Strategy” that meets the 2026 FDA reviewer expectations.